Table 1 Patient and tumor characteristics

Age (y)

56.2(± 8.0)

55.8(± 10.3)

0.85

52.1(± 15.8)

53.5(± 11.7)

0.81

0.45

Gender

0.77

0.34

0.86

 Male (n, %)

19(86.4)

46(83.6)

8(72.7)

19(86.4)

 Female (n, %)

3(13.6)

9(16.4)

3(27.3)

3(13.6)

BMI (kg/m²)

24.3 (± 2.4)

24.5 (± 3.2)

0.87

24.9 (± 3.2)

25.1 (± 4.9)

0.93

0.56

Largest dimension

(± SD, cm)

7.3(± 2.4)

6.9(± 2.8)

0.53

9.1(± 3.8)

6.8(± 3.4)

0.11

0.32

T stage

0.02

0.10

0.16

 T1 (n, %)

1(4.5)

22(40.0)

1(9.1)

11(50.0)

 T2 (n, %)

4(18.2)

5(9.1)

0(0)

1(4.5)

 T3 (n, %)

14(63.6)

22(40.0)

9(81.8)

9(41.0)

 T4 (n, %)

3(13.6)

6(10.9)

1(9.1)

1(4.5)

N stage

0.002

0.30

0.36

 N0 (n, %)

15(68.2)

52(94.5)

6(54.5)

16(72.7)

 N1 (n, %)

7(31.8)

3(5.5)

5(45.5)

6 (27.3)

Venous thrombus

(n, %)

12(54.5)

12(21.8)

0.005

6(54.5)

7(31.8)

0.21

0.15

Metastatic status

0.50

1.00

0.20

 Synchronous (n, %)

18(81.8)

41(74.5)

10(90.9)

20(90.9)

 Metachronous (n, %)

4(18.2)

14(25.5)

1(9.1)

2(9.1)

WHO/ISUP grading

0.28

0.09

0.44

 Low (1–2)

4

19

0

6

 High (3–4)

11

26

5

9

Sarcomatoid differentiation

0.72

0.57

0.63

 Present

4

3

1

3

 None

11

42

4

12

IMDC score

0.07

0.013

0.56

 Favorable (n, %)

0

3(5.5)

0(0)

2(9.1)

 Intermediate (n, %)

12(63.6)

43(78.2)

5(45.5)

18(81.8)

 Poor (n, %)

8(36.4)

9(16.4)

6(54.5)

2(9.1)

Median PFS

(m, 95%CI)

2.6(2.0, 3.2)

19.0(12.7, 25.4)

0.000

4.2(2.7, 5.8)

13.4(5.3, 21.5)

0.000

0.21

Median OS

(m, 95%CI)

55.2(51.3, 60.8)

99.2 (60.2, 121.2)

0.042

60.9(59.1, 62.7)

90.6(58.8, 118.5)

< 0.001

0.18